Lexeo Therapeutics (NASDAQ:LXEO) Shares Up 5.4%

Lexeo Therapeutics, Inc. (NASDAQ:LXEO)’s stock price shot up 5.4% on Monday . The stock traded as high as $17.09 and last traded at $16.90. 40,472 shares were traded during trading, a decline of 69% from the average session volume of 130,621 shares. The stock had previously closed at $16.04.

Analyst Ratings Changes

Several equities analysts have commented on the company. Baird R W raised Lexeo Therapeutics to a “strong-buy” rating in a report on Thursday, June 13th. HC Wainwright assumed coverage on Lexeo Therapeutics in a report on Thursday, June 6th. They issued a “buy” rating and a $22.00 price target for the company. Finally, Robert W. Baird assumed coverage on Lexeo Therapeutics in a report on Thursday, June 13th. They issued an “outperform” rating and a $28.00 price target for the company. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $22.00.

Lexeo Therapeutics Stock Down 10.2 %

The company has a quick ratio of 9.16, a current ratio of 9.16 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average price of $15.10 and a 200-day moving average price of $15.05.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its earnings results on Thursday, May 9th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.01). As a group, equities research analysts expect that Lexeo Therapeutics, Inc. will post -2.65 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new position in Lexeo Therapeutics in the 1st quarter valued at $75,000. American International Group Inc. acquired a new stake in shares of Lexeo Therapeutics in the 1st quarter valued at about $79,000. Vanguard Group Inc. raised its stake in shares of Lexeo Therapeutics by 15.8% in the 1st quarter. Vanguard Group Inc. now owns 481,755 shares of the company’s stock valued at $7,554,000 after purchasing an additional 65,573 shares during the period. Cornell University acquired a new stake in shares of Lexeo Therapeutics in the first quarter valued at about $1,980,000. Finally, Artal Group S.A. increased its position in shares of Lexeo Therapeutics by 32.9% in the first quarter. Artal Group S.A. now owns 801,716 shares of the company’s stock valued at $12,571,000 after acquiring an additional 198,281 shares during the last quarter. 60.67% of the stock is currently owned by institutional investors.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.